Neurocrine Biosciences plans to submit to the FDA a marketing application for opicapone, which is indicated for Parkinson's disease, in the first half of 2019. The agency has not asked for an additional late-stage study before Neurocrine files.
Neurocrine to seek FDA OK for Parkinson's disease therapy
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.